

# FORM 8-K

**Date of Report (Date of earliest event reported): December 27, 2023**

Securities registered pursuant to section 12(b) of the Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 27, 2023 Erick Lucera resigned as a director of the Company, effective upon the appointment of a new director. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Lucera’s years of service to the Company as a director.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 02, 2024

BONE BIOLOGICS CORPORATION

By: /s/ JEFFREY FRELICK  
Name: Jeffrey Frelick  
Title: Chief Executive Officer